Monday, December 23, 2024
HomeTagsIonis neurology

Ionis neurology

Ionis’ partner to evaluate tominersen for Huntington’s disease in new Phase 2 trial

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease (HD)....
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics